One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Athenex logo
Athenex ATNX
report update icon

Quarterly report 2022-Q3
added 06-06-2026

Athenex Income Statement 2022-2011 | ATNX

Brief overview of financial results at Athenex

The comparison covers a five-year financial horizon. Athenex reported revenue of $38 million in 2017 and $103 million by 2022. The cumulative result was +170.3%, corresponding to roughly 22% per year. Revenue growth reflects a pronounced phase of business expansion.

The gross result shifted from 12.9 million dollars to 26.7 million dollars, or +106.7%. Cost of revenue developed less favorably than sales and pressured gross profitability. Gross profit as a share of revenue changed from 34% to 26%. The business retained less gross profit from each unit of revenue.

The operating result measured by EBITDA moved from −$106 million to −$65.5 million, or +38.3%. The operating result developed less favorably than sales. EBITDA margin was −279.5% at the start and −63.7% at the end. A wider margin confirms stronger operating efficiency.

Comparing the endpoints shows a move from −131 million dollars to −103 million dollars. Losses became smaller, but the business remains unprofitable.

Market value was $791 million at the start and $11.4 million at the end. The market is not yet fully reflecting the fundamental progress.

Conclusion

Signs of deterioration dominate the five-year picture. The positive side is supported by sales growth, an improving EBITDA margin and a stronger final result. The weaker side of the profile includes a lower gross margin, a low EBITDA margin and declining capitalization. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Athenex

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

11.4 M 4.18 M 1.03 B 905 M 851 M 791 M - - - - - -

Shares

6.54 M 5.2 M 85.1 M 74.1 M 64.6 M 50 M 40.1 M 33.8 M - - - -

Historical Prices

1.75 0.805 12.1 12.2 13.2 15.8 - - - - - -

Net Income

-103 M -200 M -146 M -124 M -117 M -131 M -87.7 M -50.6 M - - - -

Revenue

103 M 95.4 M 144 M 101 M 89.1 M 38 M 20.6 M 13.9 M - - - -

Cost of Revenue

76.1 M 62.9 M 95.4 M 69.6 M 47 M 25.1 M 19.7 M - - - - -

Gross Profit

26.7 M 32.5 M 49 M 31.6 M 42.1 M 12.9 M 833 K 791 K - - - -

Operating Income

-70 M -150 M -120 M -119 M -127 M -110 M -85.7 M -50.7 M - - - -

Interest Expense

25.8 M 20.7 M 11.2 M 6.95 M 3.58 M 6.28 M 1.89 M 1 K - - - -

EBITDA

-65.5 M -145 M -115 M -115 M -124 M -106 M -83.7 M -49.8 M - - - -

Operating Expenses

96.7 M 183 M 169 M 151 M 169 M 123 M 86.6 M 51.5 M - - - -

General and Administrative Expenses

44.9 M 64.2 M 92.9 M 66.3 M 49 M 46.1 M 26 M 27 M - - - -

All numbers in USD currency

Quarterly Income Statement Athenex

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 139 M 113 M 111 M 110 M 109 M 103 M 93.4 M 93.4 M 83.7 M 81.6 M 81.5 M 81.6 M 77.3 M 73.1 M 67 M 67 M 66.4 M 63.3 M 61.7 M 58.2 M 57.1 M 43.7 M 40.7 M 40.7 M 40.3 M 39.8 M - - - - - - - - - - - - - - - - - - - - -

Net Income

- -19.7 M -32.2 M -17.4 M - -36.1 M -34.3 M -25 M -49.5 M -36.8 M -40.5 M -19.4 M -21.7 M -34.8 M -32 M -35.2 M -27.1 M -46.2 M -36.9 M -7.3 M -28.3 M -23.3 M -38.6 M -41 M -40.1 M -24.6 M -12.4 M -10.6 M - - - - - - - - - - - - - - - - - - - -

Revenue

- 33.5 M 31.5 M 29.7 M - 32.3 M 21.9 M 41 M 21.8 M 35.5 M 40.2 M 46.9 M 34.4 M 19.4 M 22.2 M 25.3 M 21.3 M 18.4 M 11.6 M 37.8 M 14.9 M 14 M 4.6 M 4.58 M 5.11 M 5.62 M 5.19 M 4.63 M - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- 27.7 M 23.1 M 23.3 M - 25.6 M 19.7 M 16.4 M 18.3 M 24.5 M 33 M 19.6 M 15.7 M 17.1 M 16.9 M 19.9 M 14.3 M 12 M 9.44 M 11.3 M 10.1 M 8.08 M 4.14 M 2.84 M - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- 5.79 M 8.42 M 6.43 M - 6.65 M 2.26 M 24.6 M 3.54 M 11 M 7.17 M 27.4 M 18.7 M 2.29 M 5.26 M 5.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- -12.9 M -21.8 M -22.5 M - -33.9 M -40.1 M -20.6 M -46.2 M -29.6 M -32.3 M -15.6 M -21.3 M -33.6 M -30.4 M -34.3 M -25.4 M -56.2 M -37.3 M -7.87 M -28.4 M -16.4 M -30.8 M -34.5 M -37.7 M -24.6 M -12.9 M -10.6 M - - - - - - - - - - - - - - - - - - - -

Interest Expense

- 6.27 M 4.31 M 4.52 M - 5.1 M 5.68 M 4.91 M - 3.6 M 1.56 M 1.67 M - 1.74 M -1.28 M -1.47 M - -1.06 M 368 K 227 K - 353 K 3.28 M -2.38 M - 5 K 49 K - - - - - - - - - - - - - - - - - - - - -

EBITDA

- -12.1 M -21.1 M -21.4 M - -32.7 M -38.9 M -19.3 M -46.2 M -28.6 M -31.3 M -14.5 M -21.3 M -32.6 M -29.5 M -33.4 M -25.4 M -55.3 M -36.3 M -7 M -28.4 M -15.5 M -29.9 M -33.6 M -37.7 M -24.1 M -12.5 M -10.6 M - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- 18.7 M 30.3 M 28.9 M - 40.5 M 42.4 M 45.2 M 49.7 M 40.6 M 39.5 M 42.9 M 39.9 M 35.9 M 35.7 M 39.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- 9.44 M 17.2 M 14.9 M - 22.8 M 21.2 M 22.1 M 31.4 M 22.2 M 17.5 M 25.7 M 18.1 M 16.3 M 17.2 M 15.2 M 11.6 M 11.5 M 12.8 M 13.1 M 12.3 M 10.4 M 13.6 M 9.8 M 10.3 M 6.79 M 4.57 M 4.34 M - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Athenex (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Drug manufacturers industry

Issuer Price % 24h Market Cap Country
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 0.96 5.83 % $ 122 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 8.33 -0.83 % $ 3.09 B canadaCanada
OrganiGram Holdings OrganiGram Holdings
OGI
$ 0.85 -2.69 % $ 81 M canadaCanada
Rockwell Medical Rockwell Medical
RMTI
$ 7.35 -2.26 % $ 264 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 3.54 1.14 % $ 177 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.12 -0.88 % $ 1.89 M usaUSA
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.74 2.96 % $ 20.1 M usaUSA
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
Pacira BioSciences Pacira BioSciences
PCRX
$ 36.48 0.04 % $ 1.63 B usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 16.83 -0.71 % $ 2.33 B usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 7.19 2.35 % $ 629 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.4 -0.36 % $ 361 M canadaCanada
Tilray Tilray
TLRY
$ 2.66 -6.84 % $ 297 M canadaCanada
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Veru Veru
VERU
$ 2.12 -3.2 % $ 31.1 M usaUSA
Viatris Viatris
VTRS
$ 20.86 1.81 % $ 23.9 B usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
cbdMD cbdMD
YCBD
$ 0.39 1.86 % $ 1.57 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.55 -2.64 % $ 2.36 M chinaChina
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.59 -5.37 % $ 176 M canadaCanada
Aurora Cannabis Aurora Cannabis
ACB
$ 5.11 -1.07 % $ 280 M canadaCanada
Harrow Health Harrow Health
HROW
$ 30.4 10.67 % $ 1.12 B usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 5.39 0.37 % $ 80.1 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.24 2.42 % $ 167 M usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.04 -0.98 % $ 323 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.43 -3.25 % $ 1.32 B canadaCanada